Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

13.51
+0.95007.56%
Post-market: 13.570.0600+0.44%19:49 EDT
Volume:4.09M
Turnover:54.96M
Market Cap:1.89B
PE:-4.04
High:13.73
Open:12.84
Low:12.76
Close:12.56
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:1.00
T/O Rate:2.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.60
PE(LYR):-3.55

Loading ...

Analysts’ Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR)

TIPRANKS
·
Jun 15

Intellia Therapeutics presents additional results from Phase 3 HAELO trial

TIPRANKS
·
Jun 15

Intellia reports Phase 3 trial shows lonvo-z cuts hereditary angioedema attacks 87% vs placebo

Reuters
·
Jun 13

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (Lonvo-Z) in Patients With Hereditary Angioedema

THOMSON REUTERS
·
Jun 13

Intellia Therapeutics - Initiates Rolling Bla Submission for Lonvo-Z; U.S. Launch Expected First Half 2027

THOMSON REUTERS
·
Jun 13

Intellia Therapeutics - Haleo Met Its Primary Endpoint With an 87% Reduction (P<0.0001) in Mean Monthly Attacks in Lonvo-Z Arm

THOMSON REUTERS
·
Jun 13

Intellia Therapeutics shareholders elect Class I directors at annual meeting

Reuters
·
Jun 11

A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise

Simply Wall St.
·
Jun 10

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 06

Intellia to present additional Phase 3 HAELO data for lonvo-z in hereditary angioedema at EAACI 2026

Reuters
·
Jun 01

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

GlobeNewswire
·
Jun 01

Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold Lift

Simply Wall St.
·
May 29

Movement Alert|Intellia Therapeutics Rises 8.01% in Regular Trading, Trading at $13.63

Market Focus
·
May 28

Stock Track | Intellia Therapeutics Plummets 8.12% Intraday on Q1 Revenue Decline and Biotech Sector Weakness

Stock Track
·
May 19

Stock Track | Intellia Therapeutics Plummets 8.33% Intraday on Q1 Revenue Decline and Sector Weakness

Stock Track
·
May 15

Intellia Therapeutics Is Maintained at Market Perform by Bernstein

Dow Jones
·
May 14

High Growth Tech Stocks In The US For May 2026

Simply Wall St.
·
May 13

Intellia Therapeutics price target raised to $17 from $13 at Bernstein

TIPRANKS
·
May 13

Intellia Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $25 From $30

THOMSON REUTERS
·
May 13

U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic

Reuters
·
May 13